Viewing Study NCT00121212


Ignite Creation Date: 2025-12-26 @ 11:13 PM
Ignite Modification Date: 2025-12-26 @ 11:13 PM
Study NCT ID: NCT00121212
Status: COMPLETED
Last Update Posted: 2015-10-30
First Post: 2005-07-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Positron Emission Tomography in Prostate Cancer
Sponsor: Washington University School of Medicine
Organization:

Study Overview

Official Title: Positron Emission Tomography in Prostate Cancer
Status: COMPLETED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.

PURPOSE: This clinical trial is studying how well positron emission tomography using carbon-11 acetate works in finding metastases and predicting recurrence in patients with prostate cancer who are at risk for recurrence after treatment.
Detailed Description: The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
R01CA101734 NIH None https://reporter.nih.gov/quic… View
P30CA091842 NIH None https://reporter.nih.gov/quic… View
WU-03-0315 None None View